T3D Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$6M
- Investors
-
3
T3D Therapeutics General Information
Description
Developer of a novel drug therapy designed to stop and reverse the course of Alzheimer's disease. The company's drug is an orally delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps treat multiple manifestations, enabling doctors to help patients to improve memory, motor function, and cognition.
Contact Information
Website
www.t3dtherapeutics.comCorporate Office
- 68 T.W. Alexander Drive
- PO Box 13628, Research Triangle Park
- Durham, NC 27709
- United States
Corporate Office
- 68 T.W. Alexander Drive
- PO Box 13628, Research Triangle Park
- Durham, NC 27709
- United States
T3D Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC (Series C) | 03-Sep-2022 | $6M | Completed | Clinical Trials - Phase 2 | ||
| 12. Grant | 15-Sep-2020 | Completed | Clinical Trials - General | |||
| 11. Grant | 01-Aug-2020 | Completed | Clinical Trials - General | |||
| 10. Later Stage VC (Series B) | 04-Nov-2019 | Completed | Clinical Trials - General | |||
| 9. Grant | 20-May-2019 | Completed | Clinical Trials - General | |||
| 8. Grant | 01-May-2019 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series B) | 10-Mar-2018 | Completed | Clinical Trials - General | |||
| 6. Early Stage VC (Series A3) | 11-Mar-2016 | Completed | Clinical Trials - General | |||
| 5. Grant | 24-Mar-2015 | $1.91M | $1.4M | Completed | Clinical Trials - General | |
| 4. Debt - General | 31-Jul-2014 | $250K | $1.4M | Completed | Startup |
T3D Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | 482,332 | $0.001000 | 6% | $1.5 | $1.5 | 1x | $1.5 | 2.88% |
| Series A1 | 404,628 | $0.001000 | 6% | $1.08 | $1.08 | 1x | $1.08 | 2.42% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
T3D Therapeutics Comparisons
Industry
Financing
Details
T3D Therapeutics Competitors (35)
One of T3D Therapeutics’s 35 competitors is CervoMed, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CervoMed | Formerly VC-backed | Boston, MA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Neurona Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Fauna Bio | Venture Capital-Backed | Emeryville, CA | ||||
| Cerecin | Venture Capital-Backed | Denver, CO |
T3D Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
T3D Therapeutics Patents
T3D Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210369680-A1 | Methods of treating diseases and disorders resulting from beta coronavirus infection | Inactive | 29-Apr-2020 | ||
| EP-3548023-A1 | Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives | Inactive | 02-Dec-2016 | ||
| US-20180153859-A1 | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype | Inactive | 02-Dec-2016 | ||
| US-20180153860-A1 | Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives | Inactive | 02-Dec-2016 | ||
| EP-3548023-A4 | Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives | Inactive | 02-Dec-2016 | A61K31/421 |
T3D Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
T3D Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alzheimers Association | Corporation | |||
| National Institute On Aging | Government | Minority | ||
| The National Institute on Aging (NIA) | Government |
T3D Therapeutics FAQs
-
When was T3D Therapeutics founded?
T3D Therapeutics was founded in 2013.
-
Where is T3D Therapeutics headquartered?
T3D Therapeutics is headquartered in Durham, NC.
-
What is the size of T3D Therapeutics?
T3D Therapeutics has 14 total employees.
-
What industry is T3D Therapeutics in?
T3D Therapeutics’s primary industry is Drug Discovery.
-
Is T3D Therapeutics a private or public company?
T3D Therapeutics is a Private company.
-
What is the current valuation of T3D Therapeutics?
The current valuation of T3D Therapeutics is .
-
What is T3D Therapeutics’s current revenue?
The current revenue for T3D Therapeutics is .
-
How much funding has T3D Therapeutics raised over time?
T3D Therapeutics has raised $32.2M.
-
Who are T3D Therapeutics’s investors?
Alzheimers Association, National Institute On Aging, and The National Institute on Aging (NIA) have invested in T3D Therapeutics.
-
Who are T3D Therapeutics’s competitors?
CervoMed, NeuroNascent, Neurona Therapeutics, Fauna Bio, and Cerecin are some of the 35 competitors of T3D Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
